Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.46 |
| ▸ | TGFBR2 | P37173 | 8/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150343 | 0.78 | TGFBR1 (0.58) | TGFBR1TGFBR2CYP3A4CYP2C8 | |
| SCHEMBL3722830 | 0.76 | TGFBR1 (0.50) | TGFBR1TGFBR2CYP3A4CYP2C8 | |
| SCHEMBL27808408 | 0.76 | TGFBR1 (0.43) | TGFBR1TGFBR2CYP3A4CYP2C8JAK2 | |
| SCHEMBL3721402 | 0.72 | TGFBR1 (0.46) | TGFBR1TGFBR2CYP3A4CYP2C8JAK2 | |
| SCHEMBL3723221 | 0.72 | TGFBR1 (0.50) | TGFBR1TGFBR2CYP3A4CYP2C8 | |
| SCHEMBL4156960 | 0.71 | TGFBR1 (0.43) | TGFBR1TGFBR2CYP3A4CYP2C8JAK2 | |
| SCHEMBL4157010 | 0.71 | TGFBR1 (0.56) | TGFBR1TGFBR2CYP3A4CYP2C8 | |
| SCHEMBL3667334 | 0.70 | TGFBR1 (0.43) | TGFBR1TGFBR2CYP3A4CYP2C8JAK2 | |
| SCHEMBL4164747 | 0.70 | TGFBR1 (0.48) | TGFBR1TGFBR2CYP3A4CYP2C8 | |
| SCHEMBL3722185 | 0.70 | TGFBR1 (0.48) | TGFBR1TGFBR2CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | claimed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | TGFBR1 128/4885TGFBR2 443/4885CYP3A4 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.